Massachusetts-based CRISPR gene editing company Verve Therapeutics has expanded its research collaboration with Eli Lilly (initially entered in June 2023) to advance the development of gene editing therapies for cardiovascular diseases. This stems from Eli Lilly's acquisition of rights to Verve's products from Beam Therapeutics.

The acquired product rights include Verve's cardiovascular in vivo gene editing programs targeting PCSK9, ANGPTL3, and an undisclosed liver-mediated, cardiovascular target, which are designed to lower low-density lipoprotein cholesterol in patients with or at risk for atherosclerotic cardiovascular disease (ASCVD).

The collaboration will allow joint development and commercialization in the US, with Verve retaining control of development and commercialization outside the US. The agreement also includes an option for Lilly to co-fund and share profits for the undisclosed disease target.

As part of Lilly’s acquisition transaction, Beam will receive a USD 200 million upfront payment and USD 50 million equity investment from Lilly and additional capital to advance its portfolio and potential future development payments, totaling a potential deal value of USD 600 million. The acquisition allows Lilly to expand its relationship with Verve and gain exposure to Beam’s base editing platform.